Compare Enveric Biosciences Inc (ENVB) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Prudential Financial Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Prudential Financial Inc trades at $122.19 (market cap $42.13B). The key difference: Prudential Financial Inc is far larger — about 6795.2× Enveric Biosciences Inc's market cap, and Prudential Financial Inc pays a 4.59% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PRU | |
|---|---|---|
Market Cap | $6.20M | $42.13B |
Sector | Health | Financials |
52-Week High | $17.40 | $123.93 |
52-Week Low | $1.27 | $92.00 |
Enterprise Value | $1.30M | $70.91B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Prudential Financial (PRU) trades at $121.28, down 0.18% today, with a bullish technical signal from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 11 and net income margin of 6.04%, supported by Q2 2026 earnings beating estimates. Recent news highlights strategic refocusing and institutional buying interest, though China tax concerns caused temporary volatility.
Outlook remains positive due to earnings beats and capital-light strategy, but risks include interest rate sensitivity and geopolitical exposure. Analyst consensus is cautious with a $110 price target below current levels, suggesting limited upside despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
